The Newsroom

Find out the latest about Calidi. Announcements, press coverage, publications, and company info—it’s all here.

Press Release

Calidi Biotherapeutics Presents Data Supporting RTNova Systemic Technology to Target Metastatic Lung Cancer

Calidi Biotherapeutics presents promising data on RTNova™, a novel systemic virotherapy technology designed to target metastatic lung cancer and other advanced cancers by overcoming immune clearance and enhancing therapeutic targeting

Discover More

In The News

event

NeuroNova

Supernova

RTNova

Calidi Biotherapeutics: A Promising Player in the Cancer Treatment Market

Calidi Biotherapeutics Inc (NYSE: CLDI) is making waves in the biotech industry with its innovative approach to cancer treatment. The company utilizes allogeneic stem cells to deliver oncolytic viruses directly to tumors, offering new hope for patients.

October 9, 2023

In The News

event

NeuroNova

Supernova

RTNova

Analyst Bullish On Calidi Biotherapeutics, Newly Listed Cancer Treatment Player

Baird initiates coverage on Calidi Biotherapeutics Inc CLDI, which uses allogeneic stem cells to deliver oncolytic viruses to tumors for cancer treatment. Just a month back, Calidi Biotherapeutics became the latest biotech to take the special purpose acquisition company route to the public market

October 9, 2023

Press Release

event

NeuroNova

Supernova

RTNova

Calidi Biotherapeutics Debuts as a Publicly Traded Company Focused on Arming the Immune System to Fight Cancer with a New Generation of Targeted Immunotherapies

Calidi Biotherapeutics, Inc. (NYSE American: CLDI or “Calidi”), a clinical-stage biotechnology company developing a new generation of targeted immunotherapies, today announced the completion of its business combination with First Light Acquisition Group (FLAG), a special purpose acquisition company. The common stock and warrants of Calidi are expected to commence trading on the New York Stock Exchange American under the ticker symbols “CLDI” and “CLDI WS,” respectively, on September 13, 2023. The stockholders of FLAG approved the transaction on August 28, 2023, following approval by Calidi shareholders. Calidi’s existing management team, including Chief Executive Officer and Chairman Allan Camaisa, will lead the combined company.

September 13, 2023

Press Release

event

NeuroNova

Supernova

RTNova

Calidi Biotherapeutics to Present at Baird’s Global Healthcare Conference

Calidi Biotherapeutics, Inc., (approved for listing on NYSE American under “CLDI”), a clinical-stage biotechnology company that is developing a new generation of targeted immunotherapies, today announced that Allan Camaisa, CEO and Chairman of the Board, and Stephen Thesing, Chief Business Officer, will participate in a fireside chat at the upcoming Baird Global Healthcare Conference on Wednesday, September 13, 2023, at 7:55 a.m. ET.

September 12, 2023

Press Release

event

NeuroNova

Supernova

RTNova

Calidi Biotherapeutics and City of Hope announce first patient dosed in a Phase 1 clinical trial evaluating neural stem cells engineered to carry an oncolytic virus, CLD-101, in recurrent high-grade glioma patients

City of Hope, one of the largest cancer research and treatment organizations in the United States and a National Cancer Institute-designated comprehensive cancer Center, and Calidi Biotherapeutics Inc. (“Calidi”), a clinical-stage biotechnology company that is pioneering the development of allogeneic cell-based delivery of oncolytic viruses, today jointly announced that the first brain tumor patient was treated at City of Hope in a multicenter, Phase 1 clinical trial evaluating CLD-101, a leading-edge therapeutic candidate in Calidi’s NeuroNova program, comprising tumor-tropic neural stem cells (NSCs) that deliver an oncolytic adenovirus — CRAd-S-pk7 — selectively to tumor sites.

July 18, 2023

Press Release

event

NeuroNova

Supernova

RTNova

Calidi Biotherapeutics Announces Commitment of $25 Million in Series B Funding to Advance Stem Cell-Based Platforms for the Delivery and Potentiation of Oncolytic Viruses to Treat Cancer

Calidi Biotherapeutics, Inc. (“Calidi”), a clinical-stage biotechnology company that is pioneering the development of allogeneic cell-based delivery of oncolytic viruses, today announced the commitment of $25 million in Series B funding led by Jackson Investment Group (“JIG”), who has funded an initial investment of $5 million, and participation from Calidi Cure, LLC, a consortium of new and existing investors led by Allan Camaisa, CEO and Chairman of Calidi. The remaining commitment is conditioned upon the consummation of the previously announced business combination between First Light Acquisition Group (NYSEAMERICAN: FLAG) and Calidi.

June 23, 2023

Press Release

Calidi Biotherapeutics Announces Two Abstracts Accepted for Presentation at AACR 2020 Virtual Annual Meeting II

SuperNova (SNV)

NeuroNova

Supernova

Delivery of oncolytic vaccinia virus by matched allogeneic stem cells overcomes critical innate and adaptive immune barriers

The Journal of Translational Medicine

March 27, 2019

Media

Scientific Advisory Board Member Interview - Ashok Srivastava, MD/PH.D.

February 3, 2024

Discover More

Media

Scientific Advisory Board Member Interview - W.K. Alfred Yung, MD

February 3, 2024

Discover More

Media

Scientific Advisory Board Member Interview - Bernard Fox, PhD,

February 3, 2024

Discover More

Media

October 9, 2023

Discover More

In The News

Analyst Bullish On Calidi Biotherapeutics, Newly Listed Cancer Treatment Player

October 9, 2023

Discover More

A talented, seasoned group of world-class executives, doctors, and scientists producing revolutionary work.

Learn more

The Newsroom

Calidi Biotherapeutics Presents Data Supporting RTNova Systemic Technology to Target Metastatic Lung Cancer

Calidi Biotherapeutics: A Promising Player in the Cancer Treatment Market

Analyst Bullish On Calidi Biotherapeutics, Newly Listed Cancer Treatment Player

Calidi Biotherapeutics Debuts as a Publicly Traded Company Focused on Arming the Immune System to Fight Cancer with a New Generation of Targeted Immunotherapies

Calidi Biotherapeutics to Present at Baird’s Global Healthcare Conference

Calidi Biotherapeutics and City of Hope announce first patient dosed in a Phase 1 clinical trial evaluating neural stem cells engineered to carry an oncolytic virus, CLD-101, in recurrent high-grade glioma patients

Calidi Biotherapeutics Announces Commitment of $25 Million in Series B Funding to Advance Stem Cell-Based Platforms for the Delivery and Potentiation of Oncolytic Viruses to Treat Cancer

Calidi Biotherapeutics Announces Two Abstracts Accepted for Presentation at AACR 2020 Virtual Annual Meeting II

Stem Cells for COVID-19 | PSC Teams Up with Calidi Biotherapeutics

Calidi Biotherapeutics Announces Appointment of Dr. George Peoples, a Prominent Immuno-Oncology Expert, to its Scientific and Medical Advisory Board

Calidi Biotherapeutics Announces Appointment of Biotech Veteran Heehyoung Lee to Board of Directors

Calidi Biotherapeutics Presents Data at the 2020 ASCO-SITC Clinical Immuno-Oncology Symposium

Calidi Biotherapeutics Announces Abstract Acceptance For Presentation at the ASCO-SITC Clinical Immuno-Oncology Symposium

Rationale for the clinical use of adipose-derived mesenchymal stem cells for COVID-19 patients

ASCO-SITC Clinical Immuno-Oncology Symposium February 6-8, 2020 Orlando, Florida.

A cell-based platform to potentiate oncolytic virus: Potential approach for cancer therapies.

First-in-human study of TK-positive oncolytic vaccinia virus delivered by adipose stromal vascular fraction cells

First-in-human study of TK-positive oncolytic vaccinia virus delivered by adipose stromal vascular fraction cells

Delivery of oncolytic vaccinia virus by matched allogeneic stem cells overcomes critical innate and adaptive immune barriers

Scientific Advisory Board Member Interview - Ashok Srivastava, MD/PH.D.

Scientific Advisory Board Member Interview - W.K. Alfred Yung, MD

Scientific Advisory Board Member Interview - Bernard Fox, PhD,

Scientific Advisory Board Member Interview - Santosh Kesari, MD/PH.D.

Big Biz TV - Allan Camaisa

Big Biz TV - Stephen Thesing

Calidi Biotherapeutics: A Promising Player in the Cancer Treatment Market

Analyst Bullish On Calidi Biotherapeutics, Newly Listed Cancer Treatment Player

All Courses

A talented, seasoned group of world-class executives, doctors, and scientists producing revolutionary work.